NO950921L - Alkylaminoindanforbindelser - Google Patents
AlkylaminoindanforbindelserInfo
- Publication number
- NO950921L NO950921L NO950921A NO950921A NO950921L NO 950921 L NO950921 L NO 950921L NO 950921 A NO950921 A NO 950921A NO 950921 A NO950921 A NO 950921A NO 950921 L NO950921 L NO 950921L
- Authority
- NO
- Norway
- Prior art keywords
- alkoxy
- halogen
- opt
- alkyl
- substd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/08—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Oppfinnelsen vedrører forbindelser med formel fl):. hvor:. Rrepresenterer et hydrogenatom eller et radikal valgt fra usubstituert eller substituert alkyl, cykloalkyl, cykloalkylalkyl, usubstituert eller substituert fenyl, og usubstituert eller substituert fenylalkyl,, Ri^og Rrepresenterer, uavhengig av hverandre, et hydrogenatom eller et radikal valgt fra halogen, usubstituert eller substituert alkyl og usubstituert eller substituert alkoksy, n representerer et helt tall fra 1 til 6, Rrepresenterer en gruppe med formel (A): hvor:R, Ri og Rn representerer, uavhengig av hverandre, et hydrogenatom eller et radial valgt fra halogen, usubstituert eller substituert alkyl og usubstituert eller substituert lavere alkoksy, - Rog Rg, sammen med benzenringen som bærer dem, danner et ringsystem Evalgt fra inden,. naftalen, benzotiofen, benzofuran, indol,. benzimidazol, benzopyran, benzotiopyran,. kroman, tiokroman, kinolin, isokinolin,. indazol, 2,3-dihydro-l,4-benzoditiin, kinoksa-lin, kinazolin, cinnolin, benzotiazol, benz-isotiazol, benzoksazol, benzisoksazol, 2,-dihydro-1,4-benzoksatiin, 1,4-benzoksazin, 1,4-benzotiazin, 1,3-benzodioksol, 1,3-benzodioksan, 1,4-benzodioksan og 1,4-benzodioksin. Medisinske produkter.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9402813A FR2717175B1 (fr) | 1994-03-11 | 1994-03-11 | Nouveaux composés alkylaminoindanes, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
Publications (2)
Publication Number | Publication Date |
---|---|
NO950921D0 NO950921D0 (no) | 1995-03-10 |
NO950921L true NO950921L (no) | 1995-09-12 |
Family
ID=9460912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO950921A NO950921L (no) | 1994-03-11 | 1995-03-10 | Alkylaminoindanforbindelser |
Country Status (16)
Country | Link |
---|---|
US (1) | US5569669A (no) |
EP (1) | EP0671397B1 (no) |
JP (1) | JP2868429B2 (no) |
CN (1) | CN1055468C (no) |
AT (1) | ATE176467T1 (no) |
AU (1) | AU679607B2 (no) |
CA (1) | CA2144288A1 (no) |
DE (1) | DE69507652T2 (no) |
DK (1) | DK0671397T3 (no) |
ES (1) | ES2130548T3 (no) |
FI (1) | FI951091A (no) |
FR (1) | FR2717175B1 (no) |
GR (1) | GR3029657T3 (no) |
NO (1) | NO950921L (no) |
NZ (1) | NZ270686A (no) |
ZA (1) | ZA952019B (no) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877218A (en) * | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
DE69732984T2 (de) | 1996-12-18 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
EP1048655B1 (en) | 1997-12-03 | 2004-09-01 | Taisho Pharmaceutical Co., Ltd | 1,2-dihydro-2-oxoquinoline derivatives |
US6737547B1 (en) | 1998-12-31 | 2004-05-18 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using N-acyl-1H-aminoindenes |
US6984652B2 (en) | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
BRPI0620659A2 (pt) * | 2005-12-09 | 2017-10-31 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica |
TW200744576A (en) * | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
CA3218884A1 (en) * | 2021-05-11 | 2022-11-17 | David Nutt | Therapeutic aminoindane compounds and compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8707123D0 (en) * | 1987-03-25 | 1987-04-29 | Pfizer Ltd | Antiarrhythmic agents |
US5140039A (en) * | 1988-01-15 | 1992-08-18 | Abbott Laboratories | Aminomethyl-thiochroman compounds |
EP0471515B1 (en) * | 1990-08-15 | 1997-03-05 | Eli Lilly And Company | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes, 3-aminochromanes and 3-aminothiochromanes |
SG65570A1 (en) * | 1992-02-25 | 1999-06-22 | Recordati Chem Pharm | Heterobicyclic compounds |
-
1994
- 1994-03-11 FR FR9402813A patent/FR2717175B1/fr not_active Expired - Fee Related
-
1995
- 1995-03-08 ES ES95400496T patent/ES2130548T3/es not_active Expired - Lifetime
- 1995-03-08 DK DK95400496T patent/DK0671397T3/da active
- 1995-03-08 EP EP95400496A patent/EP0671397B1/fr not_active Expired - Lifetime
- 1995-03-08 FI FI951091A patent/FI951091A/fi unknown
- 1995-03-08 DE DE69507652T patent/DE69507652T2/de not_active Expired - Fee Related
- 1995-03-08 AT AT95400496T patent/ATE176467T1/de not_active IP Right Cessation
- 1995-03-09 CA CA002144288A patent/CA2144288A1/fr not_active Abandoned
- 1995-03-09 AU AU14728/95A patent/AU679607B2/en not_active Ceased
- 1995-03-10 JP JP7050921A patent/JP2868429B2/ja not_active Expired - Lifetime
- 1995-03-10 NZ NZ270686A patent/NZ270686A/en unknown
- 1995-03-10 ZA ZA952019A patent/ZA952019B/xx unknown
- 1995-03-10 US US08/401,768 patent/US5569669A/en not_active Expired - Fee Related
- 1995-03-10 NO NO950921A patent/NO950921L/no unknown
- 1995-03-10 CN CN95102202A patent/CN1055468C/zh not_active Expired - Fee Related
-
1999
- 1999-03-12 GR GR990400741T patent/GR3029657T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1055468C (zh) | 2000-08-16 |
CA2144288A1 (fr) | 1995-09-12 |
NO950921D0 (no) | 1995-03-10 |
AU1472895A (en) | 1995-09-21 |
DE69507652T2 (de) | 1999-09-09 |
DE69507652D1 (de) | 1999-03-18 |
FR2717175B1 (fr) | 1996-06-14 |
FR2717175A1 (fr) | 1995-09-15 |
JP2868429B2 (ja) | 1999-03-10 |
EP0671397A1 (fr) | 1995-09-13 |
DK0671397T3 (da) | 1999-09-20 |
GR3029657T3 (en) | 1999-06-30 |
AU679607B2 (en) | 1997-07-03 |
NZ270686A (en) | 1996-05-28 |
FI951091A (fi) | 1995-09-12 |
ES2130548T3 (es) | 1999-07-01 |
US5569669A (en) | 1996-10-29 |
ZA952019B (en) | 1995-12-11 |
CN1111620A (zh) | 1995-11-15 |
JPH07278068A (ja) | 1995-10-24 |
ATE176467T1 (de) | 1999-02-15 |
EP0671397B1 (fr) | 1999-02-03 |
FI951091A0 (fi) | 1995-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO950921D0 (no) | Alkylaminoindanforbindelser | |
PE20020692A1 (es) | Compuestos derivados de benzotiofeno y su procedimiento de obtencion | |
SE9604667D0 (sv) | Hålsåg | |
PE20020230A1 (es) | Antiinflamatorios no-esteroides | |
FI910228A (fi) | Heteroaromatiska foereningar med fem ringatomer och substituerade med indol. | |
FI842843A (fi) | Leucotrienantagonister. | |
BR9708480A (pt) | Uso dos derivados das tetrahidro-beta-cabolinas como agentes antimetastáticos | |
PE20001088A1 (es) | Compuestos derivados de tetrahidrobenzazepina | |
PE68799A1 (es) | Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina | |
PE106299A1 (es) | Derivados del 2-(4-aril o heteroaril-piperazin-1-ilmetil)-1h-indol | |
ECSP034488A (es) | DERIVADOS Y ANALOGOS 10-ARIL-11H-BENZO(b) FLUORENO COMO COMPUESTOS ESTROGENICOS | |
ES8503678A1 (es) | Proceso para producir un ester de benzoilpiperazina. | |
DE60002583D1 (de) | Benzofurylpiperazine als serotonin-agonisten | |
ATE183183T1 (de) | Indol-, indazol- und benzisoxazolderivate zur behandlung von schizophrenia | |
ES2182029T3 (es) | Derivados de acido 4-(benzo-1,3-dioxolil) pirrolidin-3-carboxilico como antagonistas de endotelina. | |
KR870007149A (ko) | 하이드록시아세트산 유도체의 제조방법 | |
FR2455046A1 (fr) | Nouvelles hydantoines, leur procede de preparation et leur emploi comme medicament | |
PE20030710A1 (es) | Uso de derivados de la n-(indolcarbonil)piperazina | |
AR052260A1 (es) | Derivados de ariloxietilamina y fenilpiperazina con una combinacion de agonismo parcial del receptor de dopamina -d2 e inhibicion de la reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del sistema nervioso cent | |
DE69210959D1 (de) | Benzo(b)thiophen-2-carboxamide zur Behandlung von Krankheiten des Zentralnervensystems | |
ES528712A0 (es) | Procedimiento para preparar nuevos compuestos heterociclicos | |
KR930000496A (ko) | 항정신성 벤조디옥산 유도체 | |
MX9101928A (es) | Piperazinas substituidas como agentes del sistema nervioso central. | |
MX9206635A (es) | Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central. | |
AR011799A1 (es) | Benzamidas que tienen afinidad por el receptor d4 de dopamina, composicion farmaceutica, uso para la fabricacion de medicamentos y procedimiento deobtencion |